Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?
作者信息
Luxenburger H, Sturm L, Biever P, Rieg S, Duerschmied D, Schultheiss M, Neumann-Haefelin C, Thimme R, Bettinger D
机构信息
From the, Department of Medicine II, Faculty of Medicine, University Medical Center - University of Freiburg, Freiburg, Germany.
IMM-PACT, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
出版信息
J Intern Med. 2021 Jan;289(1):121-124. doi: 10.1111/joim.13121. Epub 2020 Jul 1.
Abstract
摘要
相似文献
1
Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?使用质子泵抑制剂治疗会增加新冠肺炎住院患者继发感染和急性呼吸窘迫综合征的风险：是巧合还是被低估的风险因素？
J Intern Med. 2021 Jan;289(1):121-124. doi: 10.1111/joim.13121. Epub 2020 Jul 1.
2
Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?质子泵抑制剂是病毒感染的风险因素：对新冠病毒感染而言也是如此吗？
Clin Drug Investig. 2020 Oct;40(10):897-899. doi: 10.1007/s40261-020-00963-x.
3
Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis.质子泵抑制剂的使用与新型冠状病毒肺炎不良临床结局风险：一项荟萃分析
J Intern Med. 2021 Jan;289(1):125-128. doi: 10.1111/joim.13183. Epub 2020 Oct 20.
4
Response to Hajifathalian and Katz Regarding Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.对哈吉法萨利安和卡茨关于质子泵抑制剂使用者中新冠病毒肺炎（COVID-19）风险增加的回应。
Am J Gastroenterol. 2020 Nov;115(11):1922-1923. doi: 10.14309/ajg.0000000000000993.
5
Reduced gastric acidity, proton pump inhibitors and increased severity of COVID-19 infections.胃酸分泌减少、质子泵抑制剂与新冠病毒感染严重程度增加
Crit Care. 2021 Feb 18;25(1):73. doi: 10.1186/s13054-021-03497-6.
6
Proton pump inhibitors in the COVID-19 pandemic.新冠疫情中的质子泵抑制剂
Gastroenterol Hepatol. 2021 Nov;44(9):611-613. doi: 10.1016/j.gastrohep.2021.04.008. Epub 2021 May 26.
7
Secondary infection among hospitalized COVID-19 patients: A retrospective cohort study in a tertiary care setting.新冠病毒肺炎住院患者的继发感染：一项在三级医疗机构开展的回顾性队列研究
Respirology. 2021 Mar;26(3):277-278. doi: 10.1111/resp.13992. Epub 2020 Dec 21.
8
Association Between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized With COVID-19.入院前使用抑酸药物与 COVID-19 住院患者疾病严重程度之间的关联。
Gastroenterology. 2021 Mar;160(4):1417-1422.e14. doi: 10.1053/j.gastro.2020.11.007. Epub 2020 Nov 12.
9
Use of proton pump inhibitors are associated with higher mortality in hospitalized patients with COVID-19.质子泵抑制剂的使用与 COVID-19 住院患者的死亡率升高有关。
J Glob Health. 2022 Feb 19;12:05005. doi: 10.7189/jogh.12.05005. eCollection 2022.
10
Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19.长期使用质子泵抑制剂是 COVID-19 住院患者死亡的一个危险因素。
Turk J Med Sci. 2021 Aug 30;51(3):1675-1681. doi: 10.3906/sag-2103-80.
引用本文的文献
1
Treatment with proton pump inhibitors is associated with secondary bacterial infections and sepsis in patients with COVID-19: a retrospective analysis of their joint impact on in-hospital prognosis.质子泵抑制剂治疗与 COVID-19 患者继发性细菌感染和脓毒症相关：联合分析对住院预后的影响的回顾性分析。
Ann Med. 2024 Dec;56(1):2399761. doi: 10.1080/07853890.2024.2399761. Epub 2024 Oct 30.
2
Proton pump inhibitors and gastrointestinal symptoms among patients with COVID-19 infection.质子泵抑制剂与 COVID-19 感染患者的胃肠道症状。
Ann Med. 2024 Dec;56(1):2355581. doi: 10.1080/07853890.2024.2355581. Epub 2024 Jun 1.
3
Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.组胺 2 受体拮抗剂和质子泵抑制剂与 SARS-CoV-2 感染风险降低相关，无论是否存在糖尿病、高血压和血脂异常等合并症：一项倾向评分匹配的全国队列研究。
J Korean Med Sci. 2023 Apr 3;38(13):e99. doi: 10.3346/jkms.2023.38.e99.
4
The Impact of Clostridioides Difficile Infection in Hospitalized Patients: What Changed during the Pandemic?艰难梭菌感染对住院患者的影响：疫情期间有哪些变化？
Diagnostics (Basel). 2022 Dec 16;12(12):3196. doi: 10.3390/diagnostics12123196.
5
Gastrointestinal prophylaxis for COVID-19: an illustration of severe bias arising from inappropriate comparators in observational studies.COVID-19 的胃肠道预防：来自观察性研究中不恰当对照导致严重偏倚的实例。
J Clin Epidemiol. 2022 Nov;151:45-52. doi: 10.1016/j.jclinepi.2022.07.009. Epub 2022 Jul 20.
6
COVID-19: gastrointestinal and hepatobiliary manifestations.新型冠状病毒肺炎：胃肠道和肝胆系统表现。
Hum Pathol. 2023 Feb;132:39-55. doi: 10.1016/j.humpath.2022.07.006. Epub 2022 Jul 16.
7
Practical points that gastrointestinal fellows should know in management of COVID-19.胃肠病学住院医师在管理新型冠状病毒肺炎（COVID-19）时应了解的实用要点。
World J Clin Cases. 2022 Jun 6;10(16):5133-5145. doi: 10.12998/wjcc.v10.i16.5133.
8
Impact of proton pump inhibitors on the in-hospital outcome of COVID-19 patients: a retrospective study.质子泵抑制剂对新型冠状病毒肺炎患者院内结局的影响：一项回顾性研究
Therap Adv Gastroenterol. 2022 Jun 14;15:17562848221104365. doi: 10.1177/17562848221104365. eCollection 2022.
9
Proton pump inhibitor therapy usage and associated hospitalization rates and critical care outcomes of COVID-19 patients.质子泵抑制剂治疗的使用与 COVID-19 患者相关的住院率和重症监护结局。
Sci Rep. 2022 May 9;12(1):7596. doi: 10.1038/s41598-022-11680-0.
10
Use of proton pump inhibitors are associated with higher mortality in hospitalized patients with COVID-19.质子泵抑制剂的使用与 COVID-19 住院患者的死亡率升高有关。
J Glob Health. 2022 Feb 19;12:05005. doi: 10.7189/jogh.12.05005. eCollection 2022.
本文引用的文献
1
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.法莫替丁的使用与住院COVID-19患者临床结局改善相关：一项倾向评分匹配的回顾性队列研究。
Gastroenterology. 2020 Sep;159(3):1129-1131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.
2
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
3
Adverse Events of Proton Pump Inhibitors: Potential Mechanisms.质子泵抑制剂的不良事件：潜在机制
Curr Drug Metab. 2018;19(2):142-154. doi: 10.2174/1389200219666171207125351.
4
Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis.门诊质子泵抑制剂治疗与社区获得性肺炎风险：一项系统评价和荟萃分析。
PLoS One. 2015 Jun 4;10(6):e0128004. doi: 10.1371/journal.pone.0128004. eCollection 2015.
5
Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis.抑酸药物的使用与肺炎风险：系统评价和荟萃分析。
CMAJ. 2011 Feb 22;183(3):310-9. doi: 10.1503/cmaj.092129. Epub 2010 Dec 20.
6
A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors.质子泵抑制剂的一般药理作用和免疫药理作用简述。
J Clin Pharm Ther. 2008 Jun;33(3):215-7. doi: 10.1111/j.1365-2710.2008.00907.x.
Zotero 插件